摘要
Abstract
OBJECTIVE:The consensus aims to evaluate the evidence regarding the off-label use of thrombopoietin receptor agonists(TPO-RA),providing evidence-based guidance for clinicians,pharmacists,and healthcare decision-makers to promote rational drug use in clinical practice.METHODS:Led by the Tumor Specialist Pharmacist Branch,Chinese Pharmacist Association,a multidisciplinary expert panel was established by using the Delphi method.Clinical questions were identified through literature retrieval,online discussion,and two rounds of external expert questionnaires.The quality of evidence was graded by using the recommended grading system for assessment,development and evaluation(GRADE),and recommendations were formed after external expert review.RESULTS:The evidence-based evaluation of TPO-RA off-label use covered 22 clinical scenarios,including oncology,acute radiation syndrome,infectious diseases,hematopoietic stem cell transplantation,pediatric severe aplastic anemia,myelodysplastic syndromes,hereditary thrombocytopenia,perioperative period of patients with immune thrombocytopenia,hemophagocytic syndrome,thrombotic microangiopathy,autoimmune diseases,and special populations.The consensus summarized the corresponding evidence and outlines key elements for rational use.A total of 9 recommendations were ultimately developed.CONCLUSIONS:Based on evidence-based medical evidence and expert clinical experience,the consensus provides certain guidance for off-label use of TPO-RA.关键词
血小板生成素受体激动剂/超说明书用药/循证评价/专家共识Key words
Thrombopoietin receptor agonists/Off-label drug use/Evidence-based evaluation/Expert consensus分类
医药卫生
